Molecular aspects of cholangiocarcinoma

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 21, Issue 6, 2014, Pages 371-379

  Kiguchi, Kaoru ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Cholangiocarcinoma; COX 2 and bile acid; Epidermal growth factor receptor erbB2

Indexed keywords

BILE ACID; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT;

ARTICLE; BILE DUCT CARCINOMA; CARCINOGENESIS; GALLBLADDER; GALLBLADDER CARCINOGENESIS; HUMAN; MOUSE MODEL; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; INTRAHEPATIC BILE DUCT; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; PROCEDURES; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84901260996     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.66     Document Type: Article

References (42)

1. Wistuba II, Gazdar AF,. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer. 2004; 4: 695-706.
2. Carriaga MT, Henson DE,. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer. 1995; 75 (1 Suppl): 171-190.
3. Cubertafond P, Gainant A, Cucchiaro G,. Surgical treatment of 724 carcinomas of the gallbladder. Results of the French Surgical Association Survey. Ann Surg. 1994; 219: 275-280.
4. Ruckert JC, Ruckert RI, Gellert K, Hecker K, Muller JM,. Surgery for carcinoma of the gallbladder. Hepatogastroenterology. 1996; 43: 527-533.
5. Oertli D, Herzog U, Tondelli P,. Primary carcinoma of the gallbladder: operative experience during a 16 year period. Eur J Surg. 1993; 159: 415-420.
6. Ogura Y, Mizumoto R, Isaji S, Kusuda T, Matsuda S, Tabata M,. Radical operations for carcinoma of the gallbladder: present status in Japan. World J Surg. 1991; 15: 337-343.
7. Kiguchi K, Carbajal S, Chan K, Beltran L, Ruffino L, Shen J, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res. 2001; 61: 6971-6976.
8. Kiguchi K, DiGiovanni J,. Role of growth factors and signal transduction pathways in biliary tract cancer. In:, Clifton Fuller M, Charles Thomas M, editors. Biliary tract and gallbladder cancer: diagnosis and therapy. New York: Demos Medical Publishing; 2009. p. 19-34.
9. Kiguchi K, DiGiovanni J,. Role of growth factor signaling pathways in biliary tract cancer. In:, Herman JTP, Thomas CR, Jr, editors. The medical radiology-radiation oncology volume on biliary tract and gallbladder cancer: a multidisciplinary approach. Heidelberg, Germany: Springer; 2014.
10. Chow NH, Huang SM, Chan SH, Mo LR, Hwang MH, Su WC,. Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. Anticancer Res. 1995; 15: 1055-1059.
11. Kawamoto T, Krishnamurthy S, Tarco E, Trivedi S, Wistuba II, Li D, et al. HER receptor family: novel candidate for targeted therapy for gallbladder and extrahepatic bile duct cancer. Gastrointest Cancer Res. 2007; 1: 221-227.
12. Kim YW, Huh SH, Park YK, Yoon TY, Lee SM, Hong SH,. Expression of the c-erbB2 and p53 protein in gallbladder carcinomas. Oncol Rep. 2001; 8: 1127-1132.
13. Ogo Y, Nio Y, Yano S, Toga T, Koike M, Hashimoto K, et al. Immunohistochemical expression of HER-1 and HER-2 in extrahepatic biliary carcinoma. Anticancer Res. 2006; 26 (1B): 763-770.
14. Suzuki T, Takano Y, Kakita A, Okudaira M,. An immunohistochemical and molecular biological study of c-erbB-2 amplification and prognostic relevance in gallbladder cancer. Pathol Res Pract. 1993; 189: 283-292.
15. Wiedmann M, Feisthammel J, Bluthner T, Tannapfel A, Kamenz T, Kluge A, et al. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anticancer Drugs. 2006; 17: 783-795.
16. Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Sugimachi K,. Tsuneyoshi M. c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology. 2002; 40: 269-278.
17. Ito Y, Takeda T, Sasaki Y, Sakon M, Yamada T, Ishiguro S, et al. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract. 2001; 197: 95-100.
18. Suzuki H, Isaji S, Pairojkul C, Uttaravichien T,. Comparative clinicopathological study of resected intrahepatic cholangiocarcinoma in northeast Thailand and Japan. J Hepatobiliary Pancreat Surg. 2000; 7: 206-211.
19. Ukita Y, Kato M, Terada T,. Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. J Hepatol. 2002; 36: 780-785.
20. Yukawa M, Fujimori T, Hirayama D, Idei Y, Ajiki T, Kawai K, et al. Expression of oncogene products and growth factors in early gallbladder cancer, advanced gallbladder cancer, and chronic cholecystitis. Hum Pathol. 1993; 24: 37-40.
21. Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res. 2006; 12: 1680-1685.
22. Terada T, Nakanuma Y, Sirica AE,. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol. 1998; 29: 175-180.
23. Kiguchi K, Ruffino L, Kawamoto T, Ajiki T, Digiovanni J,. Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. Clin Cancer Res. 2005; 11: 5572-5580.
24. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001; 61: 7196-7203.
25. Kitamura T, Connolly K, Ruffino L, Ajiki T, Lueckgen A, DiGiovanni J, et al. The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice. J Hepatol. 2012; 57: 84-91.
26. Radaeva S, Ferreira-Gonzalez A, Sirica AE,. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. Hepatology. 1999; 29: 1453-1462.
27. Yeh CN, Maitra A, Lee KF, Jan YY, Chen MF,. Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis. 2004; 25: 631-636.
28. Lai GH, Zhang Z, Shen XN, Ward DJ, Dewitt JL, Holt SE, et al. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology. 2005; 129: 2047-2057.
29. Wu Q, Kiguchi K, Kawamoto T, Ajiki T, Traag J, Carbajal S, et al. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer research. 2007; 67: 3794-3800.
30. DuBois RN, Eberhart CF, Williams CS,. Introduction to eicosanoids and the gastroenteric tract. Gastroenterol Clin North Am. 1996; 25: 267-277.
31. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE,. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology. 2002; 36: 439-450.
32. Grossman EM, Longo WE, Panesar N, Mazuski JE, Kaminski DL,. The role of cyclooxygenase enzymes in the growth of human gall bladder cancer cells. Carcinogenesis. 2000; 21: 1403-1409.
33. Kiguchi K, Ruffino L, Kawamoto T, Franco E, Kurakata S, Fujiwara K, et al. Therapeutic effect of CS-706, a specific cyclooxygenase-2 inhibitor, on gallbladder carcinoma in BK5.ErbB-2 mice. Mol Cancer Ther. 2007; 6: 1709-1717.
34. Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H,. Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res. 2005; 589: 47-65.
35. Qiao L, Studer E, Leach K, McKinstry R, Gupta S, Decker R, et al. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Mol Biol Cell. 2001; 12: 2629-2645.
36. Rao YP, Studer EJ, Stravitz RT, Gupta S, Qiao L, Dent P, et al. Activation of the Raf-1/MEK/ERK cascade by bile acids occurs via the epidermal growth factor receptor in primary rat hepatocytes. Hepatology. 2002; 35: 307-314.
37. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P,. Bile acids as regulatory molecules. J Lipid Res. 2009; 50: 1509-1520.
38. Higashiyama S, Nanba D,. ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk. Biochim Biophys Acta. 2005; 1751: 110-117.
39. Mifune M, Ohtsu H, Suzuki H, Nakashima H, Brailoiu E, Dun NJ, et al. G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. J Biol Chem. 2005; 280: 26592-26599.
40. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006; 130: 2113-2129.
41. Garzon R, Marcucci G, Croce CM,. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010; 9: 775-789.
42. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008; 322: 1695-1699.